May 08, 2019 / 06:30AM GMT
Per Walday - PCI Biotech Holding ASA - CEO
Good morning, everyone, and welcome to the First Quarter 2019 Presentation for PCI Biotech. My name is Per Walday, I'm the CEO of PCI Biotech, and I have with me also Ronny Skuggedal, who's the CFO. We will start by reviewing the highlights and thereafter, look deeper into the 3 different programs that we are developing. And thereafter, [present] a view on the financial figures and end with the outlook. And after that, we will open up for questions that is from the audience both here in the room and also from via the webcast.
Please also note our general disclaimer. So with that, let's go into the highlights.
To start with fimaCHEM. The first sites for the pivotal RELEASE study is now open for enrollment. This is the pivotal study with a gestation intent for bile duct cancer. We have now started this and will start it with 2 treatments -- up to 2 treatments of all the patients after we now had also the successful safety read-out in the Phase I extension confirmed by the Cohort Review Committee. The full Phase I study is with this completed, and
Q1 2019 PCI Biotech Holding ASA Earnings Call Transcript
May 08, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers